Resmetirom
Resmetirom's phase 3 trial showed histological benefits including steatohepatitis resolution and fibrosis improvement in the T2DM subgroup. Resmetirom is a thyroid hormone receptor-beta selective agonist that received FDA approval for MASH…
1 sources - 3 claims
Resmetirom's phase 3 trial showed histological benefits including steatohepatitis resolution and fibrosis improvement in the T2DM subgroup. Resmetirom is a thyroid hormone receptor-beta selective agonist that received FDA approval for MASH in March 2024. Resmetirom's long-term safety is unknown, with effects on the pituitary-thyroid axis unclear and only 52-week histological data available.